We have built our expertise focusing on RSV-infected children. As a result, we were able to show remarkable differences regarding growth kinetics, temperature stability, and neutralization by the monoclonal antibody palivizumab. Based on our efficient techniques, access to a clinical network to acquire live virus, and mechanisms for routine characterizations and storage (figure 2), we are able to generate high-quality virus isolates with a 94% success rate.
Figure 2 : Overview of the workflow for patient sampling, virus isolation, and sample/virus processing and characterisation.
For the respiratory virus repository, we focus on the viruses listed below.
- RSV A
- RSV B
- Enterovirus D68
- Human MPV
- Parainfluenza 1
- Parainfluenza 2
- Parainfluenza 3
- Coronavirus NL63
- Coronavirus OC43
- Coronavirus 229E
- Influenza A
- Influenza B
- Rhino virus
- Bocavirus
- Parechovirus